摘要
目的观察紫杉醇辅助化学治疗卵巢癌的临床疗效。方法选择2006年7月至2008年6月收治的卵巢癌患者104例,随机分成两组,各52例。治疗组应用紫杉醇辅助化学治疗,对照组应用异环磷酰胺辅助化学治疗,观察两组患者临床疗效及化学治疗毒副反应的发生情况。结果对照组总有效率为34.62%,治疗组为50.00%,两组差异有统计学意义(P<0.05);对照组总体生存期为1.8年,治疗组总体生存期为2.9年,两组差异有统计学意义(P<0.05);化学治疗毒副反应主要为血液学毒性、脱发、皮疹、呕吐、过敏等。结论紫杉醇辅助化学治疗卵巢癌临床疗效好,毒副反应相对较轻,患者能忍受,可在临床推广。
Objective To study the clinical efficacy of paclitaxel adjuvant chemotherapy in the treatment of ovarian cancer. Methods A hundred and four cases of ovarian cancer in our hospital from July 2006 to June 2008 were randomly divided into two groups, 52 cases in each group. The treatment group was treated with the paclitaxel adjuvant chemotherapy, while the control group received ifosfamide adjuvant chemotherapy treatment. The clinical efficacy and toxicity of chemotherapy were observed in the two groups. Results The effec- tive rate was 34. 62% in the control group and 50. 00% in treatment group, showing statistical difference between the two groups（P 〈 O. 05）. The overall survival period was 1.8 years in the control group and 2. 9 years in the treatment group with statistical difference between them （P 〈 0. 05 ）. The main toxic and adverse reactions of chemotherapy were hematologic toxicity, alopecia, rash, vomiting, aller- gies and so on. Conclusion The paclitaxel adjuvant chemotherapy for treating ovarian cancer has good effects, the toxicity is relatively mild and tolerable, which can be popularized in clinical practice.
出处
《中国药业》
CAS
2012年第7期57-58,共2页
China Pharmaceuticals
